These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 11927939)
1. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Ye Z; Hellström I; Hayden-Ledbetter M; Dahlin A; Ledbetter JA; Hellström KE Nat Med; 2002 Apr; 8(4):343-8. PubMed ID: 11927939 [TBL] [Abstract][Full Text] [Related]
2. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Yang Y; Yang S; Ye Z; Jaffar J; Zhou Y; Cutter E; Lieber A; Hellström I; Hellström KE Cancer Res; 2007 Mar; 67(5):2339-44. PubMed ID: 17332366 [TBL] [Abstract][Full Text] [Related]
3. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712 [TBL] [Abstract][Full Text] [Related]
4. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726 [TBL] [Abstract][Full Text] [Related]
5. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. May KF; Chen L; Zheng P; Liu Y Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989 [TBL] [Abstract][Full Text] [Related]
6. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460 [TBL] [Abstract][Full Text] [Related]
7. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Melero I; Johnston JV; Shufford WW; Mittler RS; Chen L Cell Immunol; 1998 Dec; 190(2):167-72. PubMed ID: 9878117 [TBL] [Abstract][Full Text] [Related]
8. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Boczkowski D; Lee J; Pruitt S; Nair S Cancer Gene Ther; 2009 Dec; 16(12):900-11. PubMed ID: 19498460 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
10. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies. Lee J; Lee EN; Kim EY; Lee HJ; Park HJ; Sun CL; Lee SK; Joh JW; Lee KW; Kwon GY; Kim SJ Transplant Proc; 2005; 37(1):123-5. PubMed ID: 15808569 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic vaccination with tumor cells that engage CD137. Hellstrom KE; Hellstrom I J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523 [TBL] [Abstract][Full Text] [Related]
12. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570 [TBL] [Abstract][Full Text] [Related]
13. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Seo SK; Choi JH; Kim YH; Kang WJ; Park HY; Suh JH; Choi BK; Vinay DS; Kwon BS Nat Med; 2004 Oct; 10(10):1088-94. PubMed ID: 15448685 [TBL] [Abstract][Full Text] [Related]
14. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. Choi BK; Bae JS; Choi EM; Kang WJ; Sakaguchi S; Vinay DS; Kwon BS J Leukoc Biol; 2004 May; 75(5):785-91. PubMed ID: 14694186 [TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion. Zhang H; Knutson KL; Hellstrom KE; Disis ML; Hellstrom I Mol Cancer Ther; 2006 Jan; 5(1):149-55. PubMed ID: 16432173 [TBL] [Abstract][Full Text] [Related]
16. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Arribillaga L; Sarobe P; Arina A; Gorraiz M; Borrás-Cuesta F; Ruiz J; Prieto J; Chen L; Melero I; Lasarte JJ Vaccine; 2005 May; 23(27):3493-9. PubMed ID: 15855007 [TBL] [Abstract][Full Text] [Related]
18. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival. Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720 [TBL] [Abstract][Full Text] [Related]
19. Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy. Wilcox RA; Flies DB; Wang H; Tamada K; Johnson AJ; Pease LR; Rodriguez M; Guo Y; Chen L Cancer Res; 2002 Aug; 62(15):4413-8. PubMed ID: 12154048 [TBL] [Abstract][Full Text] [Related]
20. Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137. Yang S; Yang Y; Raycraft J; Zhang H; Kanan S; Guo Y; Ronai Z; Hellstrom I; Hellstrom KE Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4990-5. PubMed ID: 15051893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]